Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade

Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade

Abstract CD19‐directed immunotherapy has become a cornerstone in the therapy of B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). CD19‐directed cellular and antibody‐based therapeutics have entered therapy of primary and relapsed disease and contributed to improved outcomes in relapsed diseas...

Full description

Bibliographic Details
Main Authors:	Denis M. Schewe, Fotini Vogiatzi, Ira A. Münnich, Tobias Zeller, Roland Windisch, Christian Wichmann, Kristina Müller, Hilal Bhat, Elisa Felix, Dimitrios Mougiakakos, Heiko Bruns, Lennart Lenk, Thomas Valerius, Andreas Humpe, Matthias Peipp, Christian Kellner
Format:	Article
Language:	English
Published:	Wiley 2024-02-01
Series:	HemaSphere
Online Access:	https://doi.org/10.1002/hem3.48

Similar Items

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
by: Sophia Roßkopf, et al.
Published: (2020-11-01)

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
by: Tobias Zeller, et al.
Published: (2022-10-01)

Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo
by: Dorothee Winterberg, et al.
Published: (2021-06-01)

Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.
by: Sahar Mohseni Nodehi, et al.
Published: (2012-01-01)

Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
by: Tobias Zeller, et al.
Published: (2023-09-01)

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody
by: Carina Lynn Gehlert, et al.
Published: (2022-08-01)

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
by: Lennart Lenk, et al.
Published: (2022-08-01)

511 Activity of anti-CD47 antibodies is enhanced through Fc optimization
by: Patrick Smith, et al.
Published: (2023-11-01)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
by: Siret Tahk, et al.
Published: (2021-09-01)

Tolerating CD47
by: Jeffrey S. Isenberg, et al.
Published: (2024-02-01)

Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia
by: Roland Windisch, et al.
Published: (2019-03-01)

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering
by: Franziska Heckel, et al.
Published: (2022-03-01)

Deciphering Acute Myeloid Leukemia Associated Transcription Factors in Human Primary CD34+ Hematopoietic Stem/Progenitor Cells
by: Sophie Kreissig, et al.
Published: (2023-12-01)

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
by: Niklas Baumann, et al.
Published: (2022-08-01)

CD47 is highly expressed in gliomas and targeting CD47 is a promising therapeutic strategy
by: Jiaying Yang, et al.
Published: (2021-03-01)

Role of CD47 in Hematological Malignancies
by: Entsar Eladl, et al.
Published: (2020-07-01)

Targeting CD47 for cancer immunotherapy
by: Zhongxing Jiang, et al.
Published: (2021-10-01)

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
by: Dan Zhu, et al.
Published: (2024-12-01)

Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc
by: Osman Dadas, et al.
Published: (2023-10-01)

High-affinity decoy protein, nFD164, with an inactive Fc region as a potential therapeutic drug targeting CD47
by: Zhihong Wang, et al.
Published: (2023-06-01)

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
by: Betancur, Paola A., et al.
Published: (2017)

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
by: Paola A. Betancur, et al.
Published: (2017-04-01)

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
by: Zu-Chian Chiang, et al.
Published: (2022-05-01)

The role of CD47 in non-neoplastic diseases
by: Chao Wang, et al.
Published: (2023-12-01)

Structural–functional diversity of CD47 proteoforms
by: Ting Zhang, et al.
Published: (2024-02-01)

Significance of CD47 expression in endometrial carcinoma
by: Nurhan Sahin, et al.
Published: (2022-01-01)

CD47 cross-dressing by extracellular vesicles expressing CD47 inhibits phagocytosis without transmitting cell death signals
by: Yang Li, et al.
Published: (2022-12-01)

CD47-targeted cancer immunogene therapy: Secreted SIRPα-Fc fusion protein eradicates tumors by macrophage and NK cell activation
by: Magdalena Billerhart, et al.
Published: (2021-12-01)

CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia
by: Lennart Lenk, et al.
Published: (2021-01-01)

Quantification and modeling of tripartite CD2-, CD58FC chimera (alefacept)-, and CD16-mediated cell adhesion.
by: Dustin, M, et al.
Published: (2007)

Regulation of CD47 expression on CD14+ monocytes by interferon-α in PBC patients
by: Xi Su, et al.
Published: (2023-12-01)

Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately?
by: Cristiana Tanase, et al.
Published: (2022-01-01)

Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice
by: Pulak R. Nath, et al.
Published: (2022-12-01)

CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor
by: Rami Imam, et al.
Published: (2021-03-01)

Lenk's laser handbook : featuring CD, CDV, and CD-ROM technology /
by: 361412 Lenk, John D.
Published: (1992)

TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
by: Gloria H Y Lin, et al.
Published: (2017-01-01)

Cancer Therapy Targeting CD47/SIRPα
by: Nazli Dizman, et al.
Published: (2021-12-01)

Characterization of the Pathophysiological Role of CD47 in Uveal Melanoma
by: Maria Cristina Petralia, et al.
Published: (2019-07-01)

Anticancer effects of anti-CD47 immunotherapy in vivo
by: Kristina Iribarren, et al.
Published: (2019-03-01)

CD47 as a promising therapeutic target in oncology
by: Hai Zhao, et al.
Published: (2022-08-01)